Amivantamab, an Epidermal Growth Factor Receptor (EGFR) and Mesenchymal-epithelial Transition Factor (MET) Bispecific Antibody, Designed to Enable Multiple Mechanisms of Action and Broad Clinical Applications

Cho, Byoung Chul; Simi, Allison K.; Sabari, Joshua K.; Vijayaraghavan, Smruthi; Moores, Sheri L.; Spira, Alexander I.

doi:10.1016/j.cllc.2022.11.004

Cited by 41 publications

(16 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prior to 2022, no targeted therapy was available for lung cancer patients with EGFR exon 20 insertions. At the time of this report, amivantamab is approved by the United States Food and Drugs Administration (FDA), only for subsequent lines of therapy [ 8 ]. The approval was based on data from a multi-cohort study of 81 patients who developed disease progression after platinum-based chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Amivantamab for Metastatic Lung Cancer With Paraneoplastic Disseminated Intravascular Coagulation: A Case Report

Ahmad¹,

Tanvetyanon²

2023

Cureus

View full text Add to dashboard Cite

Advanced cancers may be accompanied by paraneoplastic disseminated intravascular coagulation (DIC), resulting in thromboembolism or thrombocytopenia. Thrombocytopenia can limit the feasibility of myelosuppressive chemotherapy. Therefore, an alternative treatment option is needed. This report described a patient with metastatic pulmonary adenocarcinoma with EGFR exon 20 insertion and paraneoplastic DIC. Frontline chemotherapy failed to control the disease and worsened thrombocytopenia. However, treatment with amivantamab resulted in a rapid resolution of DIC and produced a partial tumor response. Based on our experience, for patients with EGFR exon 20 insertions with paraneoplastic DIC, amivantamab could be considered a preferred frontline treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

“…In a study of 109 patients published in 2021, chemotherapy was found superior to conventional TKIs among patients with EGFR exon 20 insertions [ 7 ]. In this report, we described our experience treating a patient with EGFR exon 20 insertions with platinum-based chemotherapy, followed by amivantamab-a novel targeted therapy [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

Amivantamab for Metastatic Lung Cancer With Paraneoplastic Disseminated Intravascular Coagulation: A Case Report

Ahmad¹,

Tanvetyanon²

2023

Cureus

View full text Add to dashboard Cite

show abstract

“…In two phase III trials, FLEX and BMS099, a combination of cetuximab and platinum doublet chemotherapy was employed to treat advanced NSCLC [ 22 , 23 ]. Additionally, amivantamab, a bispecific antibody targeting both EGFR and MET, was used to treat NSCLC specifically associated with EGFR exon 20 insertions [ 24 ]. In a preclinical study, the combination of amivantamab and lazertinib, which targets both the EGFR extracellular and catalytic domains, demonstrated synergistic tumor growth inhibition [ 25 ].…”

Section: Targeted Therapiesmentioning

confidence: 99%

Cutting-Edge Therapies for Lung Cancer

La’ah,

Chiou

2024

Cells

View full text Add to dashboard Cite

Lung cancer remains a formidable global health challenge that necessitates inventive strategies to improve its therapeutic outcomes. The conventional treatments, including surgery, chemotherapy, and radiation, have demonstrated limitations in achieving sustained responses. Therefore, exploring novel approaches encompasses a range of interventions that show promise in enhancing the outcomes for patients with advanced or refractory cases of lung cancer. These groundbreaking interventions can potentially overcome cancer resistance and offer personalized solutions. Despite the rapid evolution of emerging lung cancer therapies, persistent challenges such as resistance, toxicity, and patient selection underscore the need for continued development. Consequently, the landscape of lung cancer therapy is transforming with the introduction of precision medicine, immunotherapy, and innovative therapeutic modalities. Additionally, a multifaceted approach involving combination therapies integrating targeted agents, immunotherapies, or traditional cytotoxic treatments addresses the heterogeneity of lung cancer while minimizing its adverse effects. This review provides a brief overview of the latest emerging therapies that are reshaping the landscape of lung cancer treatment. As these novel treatments progress through clinical trials are integrated into standard care, the potential for more effective, targeted, and personalized lung cancer therapies comes into focus, instilling renewed hope for patients facing challenging diagnoses.

show abstract

“…This is a fully humanized antibody directed against mutated EGFR and mutated or amplified MET. It exerts its function both via the inhibition of the ligand binding and antibody-dependent cellular cytotoxicity ( 27 ). This drug is combined with lazertinib, a potent brain-penetrant third-generation EGFR TKI, and investigated in three clinical trials (CHRYSALIS, CHRYSALIS-2, MARIPOSA-2) for patients progressing during or after osimertinib.…”

Section: Combination Strategiesmentioning

confidence: 99%

The great need to overcome osimertinib resistance in advanced non-small cell lung cancer: from combination strategies to fourth-generation tyrosine kinase inhibitors

Bronte,

Belloni,

Calabrò

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

Amivantamab, an Epidermal Growth Factor Receptor (EGFR) and Mesenchymal-epithelial Transition Factor (MET) Bispecific Antibody, Designed to Enable Multiple Mechanisms of Action and Broad Clinical Applications

Cited by 41 publications

References 44 publications

Amivantamab for Metastatic Lung Cancer With Paraneoplastic Disseminated Intravascular Coagulation: A Case Report

Amivantamab for Metastatic Lung Cancer With Paraneoplastic Disseminated Intravascular Coagulation: A Case Report

Cutting-Edge Therapies for Lung Cancer

The great need to overcome osimertinib resistance in advanced non-small cell lung cancer: from combination strategies to fourth-generation tyrosine kinase inhibitors

Contact Info

Product

Resources

About